{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:40:33Z","timestamp":1784882433678,"version":"3.55.0"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Jiangsu Province Hospital","award":["JBGS202418"],"award-info":[{"award-number":["JBGS202418"]}]},{"name":"Jiangsu Province Hospital","award":["QY202404"],"award-info":[{"award-number":["QY202404"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cholangiocarcinoma (CCA) carries a high risk of recurrence even after curative resection. Capecitabine is standard adjuvant therapy, but recurrence rates remain significant, particularly in high-risk patients. Immunotherapy has shown promise in advanced CCA, prompting investigation into its role in earlier settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, randomised, open-label phase II trial will compare adjuvant adebrelimab plus capecitabine versus capecitabine alone in patients with high-risk resected CCA. The study is being conducted at four tertiary hospitals in Jiangsu Province, China. Eligible patients will be randomised 1:1. The primary endpoint is 1-year recurrence-free survival rate (1y-RFS rate). Secondary endpoints are overall survival, RFS and safety. Exploratory endpoints are circulating tumour DNA (ctDNA)-based MRD assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study is approved by the Institutional Review Board of Jiangsu Provincial People\u2019s Hospital (2024-SR571). Informed consent will be obtained from all participants. The findings will be published in peer-reviewed journals and presented at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06607276\">NCT06607276<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-001892","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:25:10Z","timestamp":1753863910000},"page":"e001892","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06607276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06607276","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0378-6221","authenticated-orcid":false,"given":"Yuan","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China"},{"name":"Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxian","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China"},{"name":"Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcheng","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatobiliary Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China"},{"name":"Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2026010701053310000_12.1.e001892.1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0446"},{"key":"2026010701053310000_12.1.e001892.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2026010701053310000_12.1.e001892.3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/hbsn-21-75","article-title":"Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries","volume":"12","author":"An","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026010701053310000_12.1.e001892.4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000522403","article-title":"Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma","volume":"11","author":"Kubo","year":"2022","journal-title":"Liver Cancer"},{"key":"2026010701053310000_12.1.e001892.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.06.002"},{"key":"2026010701053310000_12.1.e001892.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"2026010701053310000_12.1.e001892.7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"key":"2026010701053310000_12.1.e001892.8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026010701053310000_12.1.e001892.9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/1759-7714.13913","article-title":"SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study","volume":"12","author":"Mu","year":"2021","journal-title":"Thorac Cancer"},{"key":"2026010701053310000_12.1.e001892.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"2026010701053310000_12.1.e001892.11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial","volume":"18","author":"Yan","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026010701053310000_12.1.e001892.12","first-page":"290","article-title":"Surgical treatment and prognosis analysis of hilar cholangiocarcinoma","volume":"62","author":"Li","year":"2024","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"2026010701053310000_12.1.e001892.13","first-page":"322","article-title":"Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma","volume":"63","author":"Zhang","year":"2025","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"2026010701053310000_12.1.e001892.14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J Hepatol"},{"key":"2026010701053310000_12.1.e001892.15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MEG.0000000000002761","article-title":"An assessment of risk factors for recurrence and survival for patients undergoing liver resection for intrahepatic cholangiocarcinoma","volume":"36","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026010701053310000_12.1.e001892.16","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"2026010701053310000_12.1.e001892.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03254-6"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:06:03Z","timestamp":1767776763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjgast-2025-001892"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001892","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}